{"id":48434,"date":"2025-11-17T14:22:36","date_gmt":"2025-11-17T06:22:36","guid":{"rendered":"https:\/\/flcube.com\/?p=48434"},"modified":"2025-11-17T14:22:37","modified_gmt":"2025-11-17T06:22:37","slug":"fda-issues-boxed-warning-on-elevidys-delandistrogene-moxeparvovec%e2%80%91rokl-use-limited-to-ambulatory-dmd-patients-aged-4","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=48434","title":{"rendered":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">The U.S. Food and Drug Administration (FDA) announced a <strong>Boxed Warning<\/strong> for <strong>Elevidys<\/strong>, Sarepta Therapeutics\u2019 (<a href=\"https:\/\/www.google.com\/finance\/quote\/SRPT:NASDAQ\">NASDAQ: SRPT<\/a>) gene\u2011therapy for <strong>Duchenne Muscular Dystrophy (DMD)<\/strong>, co\u2011developed with Roche. The warning restricts the indication to <strong>ambulatory patients aged four years and older<\/strong> and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The FDA also mandates a <strong>black\u2011box label<\/strong> stating that Elevidys can cause <strong>fatal serious liver injury and acute liver failure (ALF)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-action-summary\">Regulatory Action Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Action<\/th><th>Effective Date<\/th><th>Scope<\/th><th>Key Safety Message<\/th><\/tr><\/thead><tbody><tr><td><strong>Boxed Warning<\/strong><\/td><td>14\u202fNov\u202f2025<\/td><td>All U.S. marketed Elevidys vials<\/td><td>\u201cMay cause fatal serious liver injury and acute liver failure.\u201d<\/td><\/tr><tr><td><strong>Indication Change<\/strong><\/td><td>14\u202fNov\u202f2025<\/td><td>Restricted to ambulatory DMD patients \u2265\u202f4\u202fyears<\/td><td>Non\u2011ambulatory use <strong>removed<\/strong><\/td><\/tr><tr><td><strong>EMA Status<\/strong><\/td><td>Mar\u202f2025 \u2013 Jul\u202f2025<\/td><td>Phase\u202fIII trial suspended; CHMP negative opinion<\/td><td>Conditional approval for ambulatory 3\u20117\u202fyr patients <strong>rejected<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-elevidys-product-overview\">Elevidys \u2013 Product Overview<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> Recombinant AAV\u2011mediated gene therapy delivering a <strong>micro\u2011dystrophin<\/strong> transgene.<\/li>\n\n\n\n<li><strong>Administration:<\/strong> Single intravenous infusion (\u2248\u202f0.5\u202fmL\/kg).<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Enables muscle cells to express a truncated dystrophin protein that restores ~\u202f10\u201115\u202f% of normal function, applicable to <strong>any pathogenic DMD mutation<\/strong>.<\/li>\n\n\n\n<li><strong>Approved Indication (pre\u2011warning):<\/strong> All DMD patients, ambulatory and non\u2011ambulatory, ages\u202f4\u202fyears and older.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-safety-concerns-amp-recent-events\">Safety Concerns &amp; Recent Events<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Fatal Liver Event (EU):<\/strong> In March\u202f2025, the European Medicines Agency (EMA) halted a Phase\u202fIII trial after a patient <strong>outside the trial\u2019s inclusion criteria<\/strong> suffered acute liver failure and died following Elevidys infusion.<\/li>\n\n\n\n<li><strong>CHMP Negative Opinion (Jul\u202f2025):<\/strong> The Committee for Medicinal Products for Human Use recommended <strong>against conditional approval<\/strong> for ambulatory DMD patients aged\u202f3\u20117\u202fyears, citing insufficient safety data.<\/li>\n\n\n\n<li><strong>U.S. Boxed Warning:<\/strong> The FDA now requires <strong>enhanced liver\u2011function monitoring<\/strong> pre\u2011 and post\u2011infusion, and a <strong>Risk Evaluation and Mitigation Strategy (REMS)<\/strong> for all prescribers.<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact\">Market Impact<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Outlook:<\/strong> Elevidys had generated <strong>\u2248\u202fUS$350\u202fmillion<\/strong> in 2024 U.S. sales. The restriction to a narrower patient pool (\u2248\u202f30\u202f% of the original DMD population) could cut 2025\u20112026 revenue forecasts by <strong>$120\u2011150\u202fmillion<\/strong>.<\/li>\n\n\n\n<li><strong>Stock Reaction:<\/strong> Sarepta shares fell <strong>6.8\u202f%<\/strong> in after\u2011hours trading on the announcement; Roche (NYSE:\u202fRHHBY) saw a <strong>4.2\u202f%<\/strong> decline.<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> The warning opens a window for <strong>next\u2011generation micro\u2011dystrophin candidates<\/strong> (e.g., Pfizer\u2019s PF\u201106939926) and <strong>exon\u2011skipping therapies<\/strong> to capture market share.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">This brief contains forward\u2011looking statements regarding regulatory actions, safety monitoring requirements, and financial impacts of Elevidys. Actual results may differ due to risks including additional safety findings, further regulatory actions, and competitive developments.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019&#8230;<\/p>\n","protected":false},"author":1,"featured_media":48436,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[4],"tags":[2028,68,24,2027],"class_list":["post-48434","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-policy-regulatory","tag-nasdaq-srpt","tag-pediatric-drugs","tag-rare-orphan-disease-drugs","tag-sarepta-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+ - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=48434\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+\" \/>\n<meta property=\"og:description\" content=\"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=48434\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-17T06:22:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-17T06:22:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+\",\"datePublished\":\"2025-11-17T06:22:36+00:00\",\"dateModified\":\"2025-11-17T06:22:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434\"},\"wordCount\":418,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1705.webp\",\"keywords\":[\"NASDAQ: SRPT\",\"Pediatric drugs\",\"Rare \\\/ orphan disease drugs\",\"Sarepta Therapeutics\"],\"articleSection\":[\"Policy \\\/ Regulatory\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48434#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=48434\",\"name\":\"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+ - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1705.webp\",\"datePublished\":\"2025-11-17T06:22:36+00:00\",\"dateModified\":\"2025-11-17T06:22:37+00:00\",\"description\":\"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=48434\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1705.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/1705.webp\",\"width\":1080,\"height\":608,\"caption\":\"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=48434#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+ - Insight, China&#039;s Pharmaceutical Industry","description":"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=48434","og_locale":"en_US","og_type":"article","og_title":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+","og_description":"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.","og_url":"https:\/\/flcube.com\/?p=48434","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-17T06:22:36+00:00","article_modified_time":"2025-11-17T06:22:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=48434#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=48434"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+","datePublished":"2025-11-17T06:22:36+00:00","dateModified":"2025-11-17T06:22:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=48434"},"wordCount":418,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=48434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","keywords":["NASDAQ: SRPT","Pediatric drugs","Rare \/ orphan disease drugs","Sarepta Therapeutics"],"articleSection":["Policy \/ Regulatory"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=48434#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=48434","url":"https:\/\/flcube.com\/?p=48434","name":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+ - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=48434#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=48434#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","datePublished":"2025-11-17T06:22:36+00:00","dateModified":"2025-11-17T06:22:37+00:00","description":"The U.S. Food and Drug Administration (FDA) announced a Boxed Warning for Elevidys, Sarepta Therapeutics\u2019 (NASDAQ: SRPT) gene\u2011therapy for Duchenne Muscular Dystrophy (DMD), co\u2011developed with Roche. The warning restricts the indication to ambulatory patients aged four years and older and removes the label for non\u2011ambulatory, late\u2011stage or wheelchair\u2011dependent patients.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=48434#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=48434"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=48434#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","width":1080,"height":608,"caption":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=48434#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"FDA Issues Boxed Warning on Elevidys (delandistrogene moxeparvovec\u2011rokl) \u2013 Use Limited to Ambulatory DMD Patients Aged\u202f4+"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/1705.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48434","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=48434"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48434\/revisions"}],"predecessor-version":[{"id":48437,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/48434\/revisions\/48437"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/48436"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=48434"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=48434"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=48434"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}